521 reports of this reaction
2.7% of all SIPONIMOD reports
#5 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #5 most commonly reported adverse reaction for SIPONIMOD, manufactured by Novartis Pharmaceuticals Corporation. There are 521 FDA adverse event reports linking SIPONIMOD to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 2.7% of all 19,111 adverse event reports for this drug.
Patients taking SIPONIMOD who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is a less commonly reported adverse event for SIPONIMOD, but still significant enough to appear in the safety profile.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for SIPONIMOD:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 521 FDA reports for SIPONIMOD. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 2.7% of all adverse event reports for SIPONIMOD, making it a notable side effect.
If you experience multiple sclerosis relapse while taking SIPONIMOD, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.